These results identify DRG2 as a key determinant for response of PD-L1-expressing cancer cells to anti-PD-1 therapy through regulation of intracellular localization of PD-L1 in cancer cells and as a novel therapeutic target to overcome PD-1/PD-L1-mediated immune escape of cancer cells. Here, DRG2 is linked to cancer.